Case Report: Sintilimab-induced erythroderma: a rare severe adverse event of a widely used PD-1 inhibitor
Erythroderma is a rare but severe cutaneous adverse reaction potentially associated with immune checkpoint inhibitors (ICIs), such as the PD-1 inhibitor sintilimab. Herein, we report a case of a patient with advanced gastric cancer who developed progressive generalized erythroderma (involving >90% of the body surface area, CTCAE grade 3) during sintilimab-based chemotherapy. The eruption persisted despite the discontinuation of other suspected drugs. Laboratory findings revealed marked eosinophilia and elevated IL-5 and IL-10 levels, suggesting a Th2-dominant immune response. Systemic corticosteroids provided limited improvement, while a single dose of dupilumab was followed by substantial relief of pruritus and partial resolution of erythema. However, the independent contribution of dupilumab cannot be definitively established due to concurrent therapies. This case highlights the diagnostic challenge of identifying the offending agent in combination regimens. Dupilumab may represent a potential adjunctive therapeutic option for corticosteroid-refractory ICI-induced erythroderma, warranting further investigation.
Authors
- Jueying Wang (ORCID: https://orcid.org/0000-0002-5466-5134)
- Qi Lyu (ORCID: https://orcid.org/0000-0003-4101-2334)
- Jingjing Ding (ORCID: https://orcid.org/0000-0002-9700-4504)
- Wanyue She
- Maidina Aimurula
- Xinyi Zhang
- Yu Gu
- Meng Zhou
Institutions
- Nanjing University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fmed.2026.1925289
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00